TUSTIN, CA: Exceptional Data From Bavituximab Proof-of-Concept Phase II Trial in Second-Line NSCLC Validates Platform and Positions Program for Phase III Development; Wholly-Owned Subsidiary Reports Record Revenu ...
BOTHELL, WA: Enacts Reverse Stock Split to Strengthen Financial Base; Reaffirms Commitment to Accelerate Development of First-in-Class RNA-Based Therapies for Serious and Life-Threatening Rare and Infectious Disea ...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.